LCS
DNLI icon

Levin Capital Strategies’s Denali Therapeutics DNLI Stock Holding History

Levin Capital Strategies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,000
Closed -$515K – 250
2023
Q4 		$515K Buy
24,000
+10,000
+71% +$198K 0.06% 138
2023
Q3 		$289K Buy
14,000
+6,500
+87% +$165K 0.03% 198
2023
Q2 		$221K Buy
+7,500
New +$211K 0.03% 206
2022
Q4 		– Sell
-9,500
Closed -$292K – 249
2022
Q3 		$292K Buy
9,500
+7,000
+280% +$228K 0.04% 157
2022
Q2 		$74K Buy
+2,500
New +$65.5K 0.01% 234

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Levin Capital Strategies's DNLI Position: Q1 2024 in Review

Levin Capital Strategies sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 24,000 shares — an estimated $515K sold.

Levin Capital Strategies first reported a position in DNLI in Q2 2022 and held it in 5 quarters. The position peaked at $515K in Q4 2023. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Levin Capital Strategies reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Levin Capital Strategies sold 24,000 Denali Therapeutics shares in Q1 2024, an estimated $515K.
  • Levin Capital Strategies first reported a position in Denali Therapeutics in Q2 2022 and held it in 5 quarters.
  • Levin Capital Strategies's Denali Therapeutics position peaked at $515K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Levin Capital Strategies's 13F filing for Q1 2024, filed 16 May 2024.